About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« 2011 Drug Approvals Are Up: We Rule, Right? | Main | Chinese Research: Not Quite the Juggernaut? »

July 29, 2011

Merck Announces More Big Cutbacks

Email This Entry

Posted by Derek

This is not good, not good at all: Merck is out this morning with earnings, and they're saying that they're going to cut at least 12% of their work force over the next four years. That's up to 13,000 jobs, and the word is that 35 to 40% of those cuts will be in the US.

This is after they'd already done a fair amount of restructuring after the Schering-Plough deal. And it makes a person wonder: was that deal such a good idea? Has Merck really gotten their money's worth out of it, or have they just brought on a big upheaval that could have been avoided? Going down the list of Schering-Plough assets that were advanced at the time of the acquisition, and the shape that they're in now, I really don't think it looks like something that just had to be done. Hindsight?

Comments (87) + TrackBacks (0) | Category: Business and Markets


1. Anonymous on July 29, 2011 8:13 AM writes...

So does that mean they're going to stop flooding the ACS website with jobs for plumbers?

Permalink to Comment

2. Josh on July 29, 2011 8:18 AM writes...

If they bought Schering for boceprevir, perhaps they are beginning that Vertex is going to eat them alive. Just sayin.

Permalink to Comment

3. Optimist on July 29, 2011 8:40 AM writes...

Let's hope these will all be managers/mba's and will be followed by a huge increase in research based new hires?

Permalink to Comment

4. Rick on July 29, 2011 8:45 AM writes...

I note that the article says, "The job cuts will come “disproportionately from the elimination of non-revenue generating positions,” The article doesn't say so explicitly, but that surely includes the most despicably revenue-destroying, shareholder-dissatisfying activity of all: R&D. How much R&D will be cut?

Permalink to Comment

5. You're Pfizered on July 29, 2011 9:12 AM writes...

This line was more ominous:

Ultimately, the Merck executive team would like to bring total headcount much closer to levels that existed before Schering-Plough was acquired; at the time, Merck employed about 53,000 people.

Um, that's an awful lot more people to eventually trim than just that 13K.

Permalink to Comment

6. anchor on July 29, 2011 9:16 AM writes...

No one is surprised by what is going on at Merck. I mean many companies have been doing the same..which is they are cutting their knees now and hands later. The most mind boggling issue to many is what on earth Dr. Peter Kim is doing? I mean the silence regarding his status from Merck is deafening. Can someone help us on this issue by posting the same in this blog.

Permalink to Comment

7. Hap on July 29, 2011 9:29 AM writes...

I assume the theory is "If we finished last with you, we can finish last without you", but 1) you usually can't win at baseball fielding a team of seven players and 2) they weren't finishing last before their management (including some of their scientists, presumably) decided that if something can be sold it should be oversold and having actual products of your own is overrated.

As said before, if they believe that the company is ineffective as structured, why is management still around?

Permalink to Comment

8. Anonymous on July 29, 2011 9:54 AM writes...

"perhaps they are beginning to understand...."

Permalink to Comment

9. Chemjobber on July 29, 2011 10:06 AM writes...

So the latest R&D layoffs at Pfizer were called "Project Copernicus" (according to that long Fortune article.) So what will the Merck layoffs be called?

Permalink to Comment

10. andrewD on July 29, 2011 10:10 AM writes...

chemjobber @9
Project Titanic?

Permalink to Comment

11. SteelyDan on July 29, 2011 10:25 AM writes...

Wait till GSK gets into the act. Long rumored cuts in Oncology coming. Boy, the Mid-Atlantic states are gonna resemble "Night of the Living Dead" with all the Zombie Chemists walking around.

Permalink to Comment

12. Anonymous on July 29, 2011 10:35 AM writes...

Quarterly profits of $2bn accompanied by tens of thousands of layoffs. I imagine Novartis, GSK and all the rest can't wait to follow sheep-like in Merck's footsteps. This is dire news for all.

Permalink to Comment

13. Chemjobber on July 29, 2011 10:46 AM writes...

@10 Project Hindenburg?

Permalink to Comment

14. Pig Farmer on July 29, 2011 11:00 AM writes...

@13 Pharmageddon

Permalink to Comment

15. Bubba Zinetti on July 29, 2011 11:11 AM writes...

If 2015 is the target date for this round of cuts, that means that there are people who have worked at Merck for 10 years who have known nothing but re-orgs and cuts. Nice.

Permalink to Comment

16. expharm on July 29, 2011 11:11 AM writes...

Fast Freddies Fantastic Fortune

Permalink to Comment

17. Student on July 29, 2011 12:31 PM writes...

I can't post the link but Boston Scientific is also laying off 1,200 workers according to The Boston Globe.

Permalink to Comment

18. BiotechTranslated on July 29, 2011 12:38 PM writes...

It will be interesting to see where these cuts are going to come from. Ken Fraizer has stated that continued R&D funding is what will turn Merck around (and has been spanked by the markets for it). So is Ken going back on his statement, or are these cuts going to come from non-R&D operations?


Permalink to Comment

19. Anonymous on July 29, 2011 12:41 PM writes...

Ken is saying that continued R&D will turn Merck around it is just that the R&D will be in China!

Permalink to Comment

20. Anonymous on July 29, 2011 12:46 PM writes...

So when Kim finally moves out & Rossetti moves in, who will he have left to manage?

Permalink to Comment

21. chris on July 29, 2011 12:57 PM writes...

Merck also announced dropping telcagepant, in phase III for migraine.

Permalink to Comment

22. tt on July 29, 2011 1:29 PM writes...

I guess I got out just in time...Although it was pretty obvious that this was going to be announced. A simple glance at earnings (projected) versus head count shows that Merck was not sustainable in its current size. Expect even more reductions in the future with even more reorganization, site closures, and out-sourcing. I guess 1+1 =

From a bench scientist perspective, the past 5-10 years at Merck has been disruptive to say the least where every 6 months you get a new manager and new paradigm (remember TWOOS, shots-on-goal, 6-sigma, blah, blah, blah). Layer that on top of the merger and there is little wonder why morale is at an all time low and no one feels ownership of projects or driven to give it 100% effort (or even 75%).

Expect more of the good people to leave for greener pastures, while those remaining just see it as a paycheck with an uncertain future. I really hope Merck makes it through all this as there is a load of really talented people there who love science and care about what they do, but I fear that with all of this change and strain, Merck will lose the very thing that built them.

Permalink to Comment

23. GreedyCynicalSelfInterested on July 29, 2011 1:32 PM writes...

Merck should run seminars for the people who are being laid off. Topics will include, "How to pick out a nice trailer in Nebraska," "How to collect disability," "Living with your parents," and "How to sue your employer for age, race, nationality, disability, and sex discrimination." The last seminar will be held at a bar, so the upper management won't find out. With luck, they should be able to turn it into a class-action law suit.

Permalink to Comment

24. GladToMoveToProcess on July 29, 2011 1:41 PM writes...

#18: Recent Yahoo!Finance blurb says most of the cuts will be "from headquarters and other administrative functions." An earlier piece there said Merck was reducing the upper end of their R&D budget projection slightly. No word whether the R&D will go to Chindia....

Permalink to Comment

25. @9,10,13,14 on July 29, 2011 1:45 PM writes...

Props on pharmageddon. Rolls off the tongue better than pharmapolypse or Merck-narök.

Permalink to Comment

26. #24 on July 29, 2011 1:52 PM writes...

Dude, get out of Process labwork and into CMC. American Bureaucracy won't be outsourced to Chindia anytime soon.

Permalink to Comment

27. PharmaHeretic on July 29, 2011 2:25 PM writes...

The management and leadership (virus) won't quit until they have destroyed the company (killed the host).

Permalink to Comment

28. Mike on July 29, 2011 2:29 PM writes...

Putting money into something that is broken is still something that is broken. How about going back to promoting from within, New hires reporting to experienced scientists to gain knowledge, Original thinking (no more me too), Targets that give smaller returns but more of them, Effective management, and Will someone please make a decision!! Merck is a model for how not to run a business.

Permalink to Comment

29. anchor on July 29, 2011 2:44 PM writes...

...Expect more of the good people to leave for greener pastures... What the hell are you talking about? Greener pastures where? It has been bone dry, as for as my eye can see.

Permalink to Comment

30. anonymous on July 29, 2011 2:47 PM writes...

MRL Boston has had over the last 6 months over 20% of their staff leaving of their own accord in chemistry. Rat's off a sinking ship

Permalink to Comment

31. Andy on July 29, 2011 2:48 PM writes...

So if chemists formed a union it would make things worse? Yeah right. Outsourcing is proceeding at maximum velocity.

The absence of a chemists union indicates that chemists are the weak, easily guided and disposable souls management believes them to be.

A good link below shows that most if all jobs that can be outsourced have (or will be) outsourced.

Permalink to Comment

32. Mr. Perceptive on July 29, 2011 3:24 PM writes...

Big Pharma is Big Auto and Big Steel of the 21st Century. Sclerotic and busted.

Soon, the only jobs available will be with the Leviathan Military-Security Complex.

That's if killing and destroying is your cup of tea...

Permalink to Comment

33. Mary Peed on July 29, 2011 7:00 PM writes...

I think the people at Bauch & Lomb should be getting nervous.
Pfizer bought Pharmacia and killed it (mostly).
Merck bought Schering Plough and is going to kill it.

Fred Hassan moved from Pharmacia to SP then to B&L.

Permalink to Comment

34. Anonymous on July 29, 2011 7:10 PM writes...

All management personals at large US pharma need to think this: Your fundamental management philosophy/concept at every level don't work. Whatever new buzz words you come up every year won't change anything. Let those who have true passion in drug discovery lead.

Permalink to Comment

35. DrSnowboard on July 30, 2011 1:18 AM writes...

Although Pharmageddon does trip of the tongue, how about Project Icarus or Project Somme? Depends whetheryou think pharma is about to crash and burn, or that the war will struggle on for many years with huge losses in the trenches whilst the generals sip sherry back in the chateau. Too late will they realise they need to liberate / mechanise their infantry.

Permalink to Comment

37. Anonymous on July 30, 2011 7:06 AM writes...

Sirna gone! Peter Kim next?

Permalink to Comment

38. rex on July 30, 2011 9:09 AM writes...

So long consumer health,the ship is sinking.

Permalink to Comment

39. Anonymous on July 30, 2011 2:22 PM writes...

siRNA is not "gone". That one site is gone. The work and 10 of the 50 employees are being moved to other labs on the east coast. As long as Kim survives, so too does siRNA.

Permalink to Comment

40. anonymous on July 30, 2011 6:02 PM writes...

@5. You're Pfizered

Can you please provide the source of this quote??? I, for one, think Merck will "pause", at least for awhile, at 75K employees, give or take a couple thousand.

Permalink to Comment

41. NIck on July 30, 2011 7:38 PM writes...


Permalink to Comment

42. MRKfan on July 30, 2011 8:14 PM writes...

Merck is too big. Size is holding the company back. I am a chemist at Merck and I'm excited for a company post-cuts. I think life will be easier with fewer people. It's sad, very sad, but necessary. I believe Ken Frazier will stick to a heavy investment in R&D. Heavy investment in R&D brought us Januvia, Singulair took a zillion years to discover/develop, we did good in penicillin and that was all from the lab. Ken says science is "in our DNA" and I think it's a genuine statement. I believe a smaller, R&D-focussed Merck will kick ass.

And @7. Hap: I don' think Merck is "finished" nor "last".

Permalink to Comment

43. Anonymous on July 30, 2011 9:35 PM writes...

Will you be so"excited for a company post-cuts" when you are cut too?

How will the cuts affect anything? Managers will not be cut. The same poor decision-making will persist by the self absorbed and self aggrandizing talking heads, currently known as the leadership at Merck. A decade of promotion of the loyal boot-lickers to positions requiring thoughtful vision has left Merck full of incompetents in both the highest and middle levels. Decapitation of the upper management is the only way to save Merck.

Permalink to Comment

44. You're Pfizered on July 31, 2011 9:37 AM writes...

@40--read the article in Derek's post.

Permalink to Comment

45. pharmadude on July 31, 2011 10:48 AM writes...

I thought Merk was focused on hiring the best chemists from the most elite ivy league research groups? With scientist like that, it should be impossible not to succeed?

Permalink to Comment

46. Titus on July 31, 2011 11:24 AM writes...

Let's be clear here about what the above represents.
We're experiencing is the death of the Industry as we know it.

The notion of a conspiratorial outsourcing of 'Western' pharma to China and India is an illusion - a peversely reassuring illusion even, but the cold truth is that no company is genuinely trying to rebuild its current model out there. It's closer to a frantic fiscal reshuffling to buy more time.

Don't get me wrong, the Pharmaceutical Industry has a future, a strong future.... it's just not one we can currently recognise.

And please don't be distracted by the witchhunt for a sinister cult of Harvard MBA's. It's time for us to let go of what we've got, and try and imagine a new future, one that none of us has invested in...yet.

Permalink to Comment

47. @42 MRKfan on July 31, 2011 1:55 PM writes... many products have YOU brought to market? Anyway, Januvia and Singulair will eventually be black-labeled. You're not fooling anyone, HR douchebag/uette.

FYI, singulair was discovered at Merck Frosst, which got scuttled. Merck has been corrupted by the "Pfizer Philosophy" of purchase, pillage, and burn. Yeah, a smaller R&D-focused Merck will kick in your ass out the door.

"Science is in our DNA...and so is betrayal."

Permalink to Comment

48. Anonymous on July 31, 2011 1:59 PM writes...

@42 "science was in Merck's DNA", only for the older generations, however. Somewhere down the line there was a mutation and it became "processes are in our DNA"....then another mutation and now it is "innovation is in our DNA". I hope someone can tell me the difference between science and innovation. Maybe it has something to do with the transformation from "where the patients come first" to "be well". Good luck, my friend, be well!

Permalink to Comment

49. luysii on July 31, 2011 2:17 PM writes...

Back in the 60s a variety of chemical stars gave the yearly Max Tishler Lecture at Harvard. Apparently they're still going strong. Here's where the lectures came from. Merck of all places. You've come a long way baby and it isn't good.

In 1951 Tishler was awarded the Board of Directors' Scientific Award of Merck and Company, Inc. for his achievements. Tishler used the money from this award to establish the Max Tishler Visiting Lectureship at Harvard University and the Max Tishler Scholarship at Tufts University. In 1953 he was elected to the National Academy of Sciences.

Tishler was named vice president of scientific activities at Merck in 1954, and in 1956 he became president of the Merck laboratories. He held that position until 1969, when he took over as senior vice president of research and development until his retirement in 1970. During his 33 years at Merck, Tishler was responsible for the development of a wide range of new drugs for the treatment of infections, growth disorders, heart disease, hypertension, mental depression, and several inflammatory diseases, such as arthritis.

Permalink to Comment

50. Anonymous on July 31, 2011 3:05 PM writes...

Politics is in Merck's DNA. You will know what I meant if you would take a look at this article. The guy has done nothing at Merck in his whole career, but knows how to play clown and politics.

Permalink to Comment

51. @50 on July 31, 2011 4:46 PM writes...

Dude is really rockin' the bowtie. I fail to understand why anyone nowadays would want to work in Big Pharma and be the mercy of bottomfeeders and robber-barons. There has to be an easier way of making $90-120K a year without having to burn up most of your 20s and expose yourself to toxic chemicals and people.

Permalink to Comment

52. @14 on July 31, 2011 4:55 PM writes...

Sorry, I think Pfarmageddon has already happened. Just ask the forsaken from Pharmacia-Upjohn, Parke-Davis, Wyeth-Ayerst, and a bunch of biotechs.

Permalink to Comment

53. Anonymous on July 31, 2011 5:08 PM writes...

@50 Thanks for the article. I found it very interesting that after 300 deals and a 10-year efforts, all Turner could show was GlycoFi?....Not a drug that is pulling billions, not a candidate that is waiting for FDA's final stamp.... Maybe this guy was being modest here, but I found it pathetic. Could someone forward the article to Merck Board of Directors, they should consider denying this guy's pension.

Permalink to Comment

54. Anonymous on July 31, 2011 5:53 PM writes...

Things went downhill when they 6-stigmatized, booted the old talent, and leveled MF.

Still a lot of talent there, but much of it is leaving or frustrated.

If you are talented and you know it raise your hand.

The amount of time spent on creating new paradigms, synergizing, and software solutions to phantom problems is just mind boggling.

A large part of the blame lands squarely on very weak senior R&D leadership. Companies with vision and courage act purposely. They don't flail around trying to band-aide their way out of the problem.

Combi-chem, 6-sigma, outsource, in-license.

These are tools and options not business strategy.

@34 nailed it.

A prime example of a once great company with rock solid values and world leading talent becoming a hollowed out to a shell.

I hope that Mckinsey's plan pulls through, because it won't take much to sink this boat.

Permalink to Comment

55. @50 on July 31, 2011 6:26 PM writes...

I agree. That is why the undergrads with a biological background that could go to grad school now go to Medical/Pharmacy/Optometry/Dentistry/Nursing schools...Those careers only put out X degrees a year (they are limiting by certain governing oranizations)...and this is why most of the graduating PhDs are from Inia and China.

Permalink to Comment

56. Recovering merckie on July 31, 2011 7:51 PM writes...

Its just really sad to see Merck being destroyed by incompetent management, hiring and promotion policies focused on inbreeding, and general lack of leadership and understanding of how to do business in the modern marketplace. What a great company it once was, and what has become of it....

Permalink to Comment

57. Anonymous on July 31, 2011 8:04 PM writes...

@ 50. Besides his clown skills, he is good with people's names. I recall that he impressed everyone at Merck Frosst be addressing all the employees he came across in hallway by their first names soon after he was made site head of Merck Frosst. He must have spent a lot of his time memorizing people's names. The guy is such a fake. But it apparently worked for him even though it disheartened all the scientists who had to watch guys like him get promoted faster than anyone else.

Permalink to Comment

58. Anonymous on July 31, 2011 9:23 PM writes...

OK all you Merck ship jumpers...head on over to Roche in Nutley....just a short ride up the GSP. If you do, talk to people and understand that you will be making a big mistake....buying 1 -2 yrs. max of time. Nutley is going down...

Permalink to Comment

59. Anonymous on July 31, 2011 9:30 PM writes...

I heard Roche is looking for a head of inflammation chemistry in Nutley NJ...why did the previous head leave?? Perhaps it's the inverted reporting structure over there ie: Ph.D's reporting to MSc's etc...

That's how you destroy shareholder value and morale!!!

Permalink to Comment

60. Anonymous on July 31, 2011 9:41 PM writes...

Merck Rahway NJ...declared a logtime drug free zone!! Great for the nearby schools, bad for business...

Permalink to Comment

61. anonymous on July 31, 2011 9:41 PM writes...

For all you Merckies (past and present out there) -
I wonder what the ROI from all of Merv's licensing "deals" has been over the years???????

Permalink to Comment

62. Anonymous on July 31, 2011 9:52 PM writes...

The closure of Merck Frosst was a decision Merck will have to live with going forward. It marked the demise of a once respected company. Frequently nonsense and moronic behavior occurs but in the end justice prevails..always

Permalink to Comment

63. Anonymous on July 31, 2011 11:43 PM writes...

@59. Wow, a Ph.D reporting to a non-Ph.D! If only experience mattered beyond graduate school. After all, a Ph.D in organic chemistry clearly prepares a scientist to lead drug discovery programs. People wonder what is wrong with the industry?

Permalink to Comment

64. Jose on August 1, 2011 1:58 AM writes...

Re 54. Anon, "I hope that Mckinsey's plan pulls through, because it won't take much to sink this boat."

Having seen it up close, I am pretty damn certain McKinsey's and BCG's management snake-oil-voodoo-mumbo-jumbo-cutNpaste "expert analysis" idiocy is only hastening the demise of pharma while they cackle all the way to the bank....

Permalink to Comment

65. Merckistan on August 1, 2011 7:48 AM writes...

@59: I wouldn't mind reporting to a non-PhD, especially if that person has something to teach me and is otherwise nice. What's really distressing is that supposedly science-based companies are being led into the crapper by non-scientists.

@39: So, are you one of the final 10 cylons?

Permalink to Comment

66. MedChem on August 1, 2011 11:36 AM writes...

#42, 47:

One of the chemists who made critical contributions to the discovery of Januvia was layed off by Merck quite a while ago.---so the boss could claim credit unhindered?

Permalink to Comment

67. anchor on August 1, 2011 12:00 PM writes...

# 42 - you a brown nose or what?

Permalink to Comment

68. Zippy on August 1, 2011 1:58 PM writes...

Few are surprised by the recent announcement. Just another phase in the death spiral. And future prospects do not appear more sanguine due to: significant drop-off in MRL productivity post BRGOS, a significant overvaluation of SP assets and capabilities, and ongoing turmoil and de-motivation.

The merger with SP follows from the transformation of Merck from a science and medicine driven company to a process based organization. Given this, acquisitions may be one of the few choices to forestall collapse. It may seem unlikely to business minded folks, but Merck’s earlier business successes followed from focusing on the science and medicine.

@42, Mr. Optimist.
If you are familiar with the history of the products you mention, or if you examined the patents supporting these products, you would notice that many key investigators are no longer with MRL.

Permalink to Comment

69. Anonymous on August 1, 2011 6:21 PM writes...

Looks Like research at MRL Rahway is over. Now just process and chenistry support, no biology. Kenilworths better facilities won over for the bean counters.

Permalink to Comment

70. Anonymous on August 1, 2011 7:46 PM writes...

why keep two sites that are so close? It doesnt make sense. I agree with 58. I didnt jump ship for that reason. Nutley will probably be closed within a couple of years. Hope that Merck will stay afloat for a little longer!

Permalink to Comment

71. Anonymous on August 1, 2011 8:27 PM writes...

@59 & 63: Here's the Roche Posting

Note: no mention of education requirements ...why is that? What's going on over there?

Permalink to Comment

72. Anonymous on August 1, 2011 9:20 PM writes...

There are three ways to improve the books.
1. Launch products
2. Close sites
3. Cut people, oops, I mean headcount, FTEs, or resources, fixed costs, or any other word in vogue so we don't have to use the word "people"

We are not launching enough drugs, and we are maintaining sites, ergo, the people must go...PK and RT can just hire newbies at record-setting low salaries to fill the gaps at these sites...great plan...right? And O/S even more! We don't need experience, we just need that glorious Merck management vision. Everyone is just going to stay focused and "Be well." There is a well-known bridge for sale too...

Permalink to Comment

73. Anonymous on August 2, 2011 9:56 PM writes...

- Demonstrated business skills:
- Presentation/ Communication = BS
Influencing/Negotiating = kiss As
- Delegating = ask admin to order lunch
- Interfacing = spend even more time at meetings
- Organization and change management skills = know how to move people from office to cubicles
- Demonstrated skills in talent growth, scientific and leadership development and the ability to motivate employees to work at their greatest potential = know how to put people on PIP

Degree = who cares about PhD

Permalink to Comment

74. Anonymous on August 2, 2011 10:08 PM writes...

Minimum of 10 years of related (to what?)experience with at least five years managing teams
- Recognized (by whom) strong scientific background in organic synthesis and medicinal chemistry
- Ability to build, engage, energize and focus (how about motivate and empower?) a strong team of chemists
- Demonstrated ability to drive results (without driving people nuts)
- Ability to successfully resource projects in a flexible manner including efficient use of outsourcing (to prepare for the next round of job cuts)
- Broad (know a thing or two) understanding of the drug discovery process
- Strategic thinker (knows how to prepare PPT) with solid capabilities to successfully deliver on short/long-term goals
- Customer and partnership focus, listens and responds proactively to internal business partner needs and concerns-demonstrated success in relationship management with scientific partners and technical clients (listen and nod)
- Able to handle stressful situations in a dynamic and fast paced environment (relax and smile)
- Effective at cultivating interpersonal relationships in order to establish working relationships with direct reports, peers, and colleagues (say yes and smile)

Permalink to Comment

75. Anonymous on August 2, 2011 10:18 PM writes...

73+74 = Roche culture at its finest!

Permalink to Comment

76. Anonymous on August 3, 2011 7:21 PM writes...

@73 - 76 you guys are spot on!!! Ok, which ones work for Roche??? Just kidding...

I think they should recruit exclusively from Montclair state U LOL

Permalink to Comment

77. Anonymous on August 3, 2011 8:09 PM writes...

@66 My guess is that the guy responsible for Januvia was in an unfortunate situation. This is the main problem with upper management in big pharma...especially if they're old school. If they don't like you, and you don't kiss their A$$ then you will fall victim to the "perception building" and you will be caged, tainted, dogged and held captive by the fiends. Sad, sad sad, when you can't defend yourself cause you're not aware of what is being said behind closed doors! When the time comes for a layoff, all it takes is a nod and you're gone!! This is the toxic mess that is plagueing big pharma.

For those victims out there ...just remember...justice always prevails in the end. YOU WILL BE VINDICATED!!

Permalink to Comment

78. Anonymous on August 4, 2011 1:36 AM writes...

A close examination of the SF site would tell you there is a very small number of talent there. That's why they shut it down.

Permalink to Comment

79. Anonymous on August 4, 2011 1:43 AM writes...

SIX SIGMA training for everyone!!! That should help you with your research and development Merck!!!

Permalink to Comment

80. Anonymous on August 4, 2011 2:00 AM writes...

Who is going to do R&D, if all of the jobs are being out sourced? What's next Merck Rahway goes to China? It is disheartening to see the poor decisions on drug R&D being made by people who don't know anything about science.

Permalink to Comment

81. anonymous on August 4, 2011 6:47 AM writes...

@82 - Answer to your 2nd question = YES.

Permalink to Comment

82. Anonymous on August 5, 2011 6:50 AM writes...

76. People tend to talk about their own companies, especially when it comes to dirty laundries. Which department of Roche do you work in?

Permalink to Comment

83. Anonymous on August 5, 2011 5:20 PM writes...

Merck's in 1st place!!! As their CEO lies to them about investing in R&D, can never trust a laywer to lead a drug company. At least Pfizer's CEO was upfront about it when he said they are going to have major layoffs.

Permalink to Comment

84. Anonymous on August 18, 2011 2:49 PM writes...

West Point asking for hand raisers and will be notified by Oct. 31st.

Permalink to Comment

85. Anonymous on August 18, 2011 2:50 PM writes...

West Point asking for hand raisers and will be notified by Oct. 31st.

Permalink to Comment

86. Nut Sachs on September 12, 2011 1:20 AM writes...

Merck is a joke, they hire to retire their friends not to retain good researchers. Only to have college buddies become VP and then give them seven figure salaries and retire packages.

Permalink to Comment

87. Anonymous on September 30, 2011 10:12 AM writes...

Any hand raisers let go yet?

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry